NCT01001793终止不适用
Evaluation of the Levacor™ Ventricular Assist Device as a Bridge to Cardiac Transplantation
World Heart Corporation12 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2009年8月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 15
- 试验地点
- 12
- 主要终点
- Success is defined as any one of the following: survival to cardiac transplantation prior to 180 days, survival on device to 180 days, device removal for recovery and survival to 60 days after device removal
研究概览
简要总结
The Levacor™ Ventricular Assist Device (VAD) has been designed for mechanical circulatory support in heart failure patients. The purpose of this clinical study is to determine its safety and efficacy as a bridge to transplant (BTT) in cardiac transplant candidates with presumed non-reversible left ventricular failure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must be at least 18 years of age at the time of VAD implantation.
- •Listed for cardiac transplantation as UNOS Status 1A or 1B at the time of VAD implantation or within 72 hours of VAD implantation.
- •Body Surface Area (BSA) 1.2 m2 or greater.
- •If female of childbearing potential must have negative pregnancy test.
- •Patient has signed an Informed Consent.
排除标准
- •Unacceptable surgical risk according to Principal Investigator.
- •Intolerance or contraindication to anticoagulation or antiplatelet therapies.
- •Excessive risk of bleeding as evidenced by INR > 2.3, or PTT > 45 sec, or platelet count < 50,000 U, unresponsive to treatment.
- •Excessive neurologic risk documented as TIA within the last 3 months or stroke within the last 6 months.
- •Evidence of any of the following indicators of end-organ dysfunction: total bilirubin > 4 mg/dL, ALT/AST > 3 times upper limit normal, serum creatinine >3.5 mg/dL.
- •Fixed pulmonary hypertension with a most recent PVR > 5 Wood units unresponsive to pharmacological intervention.
- •Severe chronic obstructive pulmonary disease as evidenced by an FEV1 < 1.0 L or restrictive lung disease or prolonged (> 48 hours) intubation.
- •Presence of mechanical aortic valve that will not be converted to a bioprosthesis during VAD implantation.
- •Planned concomitant surgical procedures other than aortic valve repair or tissue valve placement to treat moderate to severe aortic insufficiency, tricuspid valve repair, mitral valve repair, critical lesion CABG, LV thrombectomy (apical), closure of persistent foramen ovale, atrial septal defect.
- •Cardiogenic shock secondary to acute myocardial infarction.
- •Presence of ongoing mechanical circulatory support other than intra-aortic balloon counterpulsation.
- •Presence of uncontrolled infection.
- •BMI > 40 kg/m
- •Significant peripheral vascular disease accompanied by pain at rest, extremity ulceration or disabling claudication.
- •Illness, other than heart disease, that would limit survival to less than 1 year.
- •Pulmonary embolus < 2 weeks before VAD implant.
- •Poor/compromising nutritional status in judgment of Principal Investigator.
- •Participation in another clinical trial that, according to the Principal Investigator, is likely to affect the Study outcome or confound the results.
结局指标
主要结局
Success is defined as any one of the following: survival to cardiac transplantation prior to 180 days, survival on device to 180 days, device removal for recovery and survival to 60 days after device removal
时间窗: 6 months
次要结局
- Survival to transplant(6 months)
- Survival 30 days post-transplant(6 months)
- Survival while on device(6 months)
- Incidence of adverse events while on device(6 months)
- Device reliability(6 months)
- Reoperations(6 months)
- Functional status(6 months)
- Quality of life(6 months)
- Neurocognitive evaluation(6 months)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility TrialCardiomyopathiesEnd-Stage Heart FailureNCT00490347Ventracor30
Unknown
3 期
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal TrialCardiomyopathiesEnd-stage Heart FailureNCT00483197Ventracor140
Unknown
3 期
VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination TherapyCardiomyopathiesEnd-stage Heart FailureNCT00490321Ventracor225
撤回
1 期
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device SupportLeft Ventricular Assist DeviceNatriuretic PeptideHeart FailureNCT03091998Mayo Clinic
已完成
4 期
Efficacy Study of LV Assist Device to Treat Patients With Cardiogenic Shock (ISAR-SHOCK)Shock, CardiogenicMyocardial InfarctionNCT00417378Deutsches Herzzentrum Muenchen26